Dr. Mark Gurney
CHAIRMAN & CEO, TETRA DISCOVERY PARTNERS, INC.
Grand Rapids, Michigan, United States
Dr. Mark Gurney founded Tetra Discovery Partners as a drug development company in 2011 to develop meaningful medications for large unmet needs including Alzheimer’s disease. He has held positions in academia and within the pharma industry. Dr. Gurney was named one of two leading inventors in the field of Alzheimer’s Disease therapeutics for his discovery of the beta-secretase, a key enzyme in the amyloid pathway that releases the A-beta peptide from the amyloid protein precursor. Dr. Gurney’s resume with biotech companies includes work in drug discovery and development as Senior Vice President at deCODE genetics, Inc.; Director Genomics, Pharmacia Corporation; Associate Professor, Northwestern University Feinberg School of Medicine; and Assistant Professor, University of Chicago Medical School. In addition to his work on Alzheimer’s disease, Dr. Gurney developed the SOD1-G93A transgenic mouse model of ALS. Dr. Gurney has authored 117 peer reviewed papers that have been cited over 18,000 times and holds 36 issued patents. He earned a PhD in neuroscience from the California Institute of Technology and an MBA from the Kellogg Graduate School of Management at Northwestern University.
1:00 PM - 2:15 PM
Monday, June 3
Opportunities for Industry within Government Neuroscience Initiatives to Tackle Difficult Health Challenges
As noted in the BRAIN 2025 report, the burden of human brain disorders is significant. Over five…